scholarly journals Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients

Oncotarget ◽  
2016 ◽  
Vol 7 (15) ◽  
pp. 21034-21045 ◽  
Author(s):  
Qiong Yang ◽  
Fangxin Liao ◽  
Yuanyuan Huang ◽  
Chang Jiang ◽  
Shousheng Liu ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5547
Author(s):  
Carolina de la Pinta ◽  
María E. Castillo ◽  
Manuel Collado ◽  
Cristina Galindo-Pumariño ◽  
Cristina Peña

Radiomics is a developing new discipline that analyzes conventional medical images to extract quantifiable data that can be mined for new biomarkers that show the biology of pathological processes at microscopic levels. These data can be converted into image-based signatures to improve diagnostic, prognostic and predictive accuracy in cancer patients. The combination of radiomics and molecular data, called radiogenomics, has clear implications for cancer patients’ management. Though some studies have focused on radiogenomics signatures in hepatocellular carcinoma patients, only a few have examined colorectal cancer metastatic lesions in the liver. Moreover, the need to differentiate between liver lesions is fundamental for accurate diagnosis and treatment. In this review, we summarize the knowledge gained from radiomics and radiogenomics studies in hepatic metastatic colorectal cancer patients and their use in early diagnosis, response assessment and treatment decisions. We also investigate their value as possible prognostic biomarkers. In addition, the great potential of image mining to provide a comprehensive view of liver niche formation is examined thoroughly. Finally, new challenges and current limitations for the early detection of the liver premetastatic niche, based on radiomics and radiogenomics, are also discussed.


2019 ◽  
Vol 11 (513) ◽  
pp. eaay2574 ◽  
Author(s):  
Salo N. Ooft ◽  
Fleur Weeber ◽  
Krijn K. Dijkstra ◽  
Chelsea M. McLean ◽  
Sovann Kaing ◽  
...  

There is a clear and unmet clinical need for biomarkers to predict responsiveness to chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC). In a prospective clinical study, we show the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy. Our PDO test predicted response of the biopsied lesion in more than 80% of patients treated with irinotecan-based therapies without misclassifying patients who would have benefited from treatment. This correlation was specific to irinotecan-based chemotherapy, however, and the PDOs failed to predict outcome for treatment with 5-fluorouracil plus oxaliplatin. Our data suggest that PDOs could be used to prevent cancer patients from undergoing ineffective irinotecan-based chemotherapy.


2018 ◽  
Vol 37 (11) ◽  
pp. 1015-1024
Author(s):  
Fabiola Müller ◽  
Marrit A. Tuinman ◽  
Ellen Stephenson ◽  
Ans Smink ◽  
Anita DeLongis ◽  
...  

2019 ◽  
Author(s):  
Julia Sánchez-Gundín ◽  
Cristina Martín-Sabroso ◽  
Ana M. Fernández-Carballido ◽  
D. Barreda-Hernández ◽  
Ana I. Torres-Suárez

Sign in / Sign up

Export Citation Format

Share Document